In recent years, some Silicon Valley billionaires have become enthusiastic about an anti-aging therapy dubbed ‘young plasma transfusion’—infusing blood plasma from young donors (typically aged 18–25) in hopes of slowing aging, boosting energy, or even enhancing cognitive function. This practice stems from early animal studies showing that infusing young mouse blood into older mice led to improvements in certain physiological markers. However, there is currently no robust clinical evidence proving its anti-aging efficacy in humans.The U.S. Food and Drug Administration (FDA) has issued multiple warnings stating that such ‘young plasma infusions’ lack scientific validation and carry potential health risks, including infections, immune reactions, and ethical concerns. Despite this, some tech elites continue to pursue it as a form of ‘biohacking,’ either trying it privately or investing in related startups. Proponents view it as an early step toward regenerative medicine, while critics dismiss it as pseudoscience—a modern-day vampire myth dressed in scientific language.Overall, ‘young plasma transfusion’ remains on the fringes of experimental science. It is neither endorsed by mainstream medicine nor supported by large-scale, double-blind, placebo-controlled trials. As the quest for longevity continues, maintaining scientific skepticism and distinguishing genuine innovation from pseudoscientific hype is crucial.
近年来，硅谷部分富豪热衷于一种被称为“三代换血”的抗衰老疗法，即通过输入年轻人（通常是18-25岁）的血浆，试图延缓自身衰老、提升精力甚至改善认知功能。这一做法源于一些早期动物实验——例如将年轻小鼠的血液注入老年小鼠后，后者在某些生理指标上出现改善。然而，目前尚无确凿临床证据表明该疗法对人类具有显著抗衰老效果。美国FDA曾多次警告，称此类“年轻血浆输注”缺乏科学依据，且存在潜在健康风险，包括感染、免疫反应和伦理问题。尽管如此，部分科技精英仍将其视为“生物黑客”手段之一，私下尝试或投资相关初创公司。支持者认为这是未来再生医学的雏形，而批评者则斥之为披着科学外衣的“现代吸血鬼”行为，更接近玄学而非严谨科学。总体而言，“三代换血”目前仍处于实验边缘地带，既未被主流医学认可，也缺乏大规模、双盲、对照的临床试验支持。在追求长寿与青春的道路上，理性对待新兴技术、警惕伪科学包装，显得尤为重要。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/17450.html